AMAG PHARMACEUTICALS, INC.: 10-Q filed 2014-05-05
What AMAG PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-05-05 (fiscal Q1 2014): 29 published measures, 62 facts as tagged in accession 0001104659-14-034303.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-05-05
- Fiscal period
- fiscal Q1 2014
- Accession
- 0001104659-14-034303 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All AMAG PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 446,463,000 | USD | |
| At 2013-12-31 | 265,459,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 255,367,000 | USD | |
| At 2013-12-31 | 93,051,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 191,096,000 | USD | |
| At 2013-12-31 | 172,408,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 200,916,000 | USD | |
| At 2013-12-31 | 26,986,000 | USD | |
| At 2013-03-31 | 33,845,000 | USD | |
| At 2012-12-31 | 46,293,000 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 124,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 23,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | -473,362,000 | USD | |
| At 2013-12-31 | -466,260,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 1,837,000 | USD | |
| At 2013-12-31 | 1,846,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,930,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 2,283,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 421,004,000 | USD | |
| At 2013-12-31 | 244,405,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,476,000 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 36,094,000 | USD | |
| At 2013-12-31 | 33,121,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 5,125,000 | USD | |
| At 2013-12-31 | 2,629,000 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 16,815,000 | USD | |
| At 2013-12-31 | 16,844,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 10,115,000 | USD | |
| At 2013-12-31 | 6,842,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 20,804,000 | USD | |
| At 2013-12-31 | 17,217,000 | USD | |
| At 2013-03-31 | 11,292,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 17,491,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 14,005,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 21,877,192 | shares | |
| At 2013-12-31 | 21,772,571 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | -3,414,000 | USD | |
| At 2013-12-31 | -3,491,000 | USD | |
| At 2013-03-31 | -3,340,000 | USD | |
| At 2012-12-31 | -3,247,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 2,412,000 | USD | |
| At 2013-12-31 | 2,342,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 575,000 | USD | |
| At 2013-12-31 | 496,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 6,407,000 | USD | |
| At 2013-12-31 | 1,964,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 21,851,000 | USD | |
| At 2013-12-31 | 22,266,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 4,410,000 | USD | |
| At 2013-12-31 | 3,396,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -7,025,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | -3,988,000 | USD | 90 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -7,102,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | -3,895,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 162,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 650,000 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -1,111,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 576,000 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 3,273,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 2,109,000 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 2,521,000 | USD | 90 |
| 2013-01-01 to 2013-03-31 | -1,834,000 | USD | 90 |
Inspect the source
- Entity
- AMAG PHARMACEUTICALS, INC. / CIK 0000792977
- Captured
- SEC response SHA-256
d9987b965b5869d8e9b2eeb307cd76b9cd461348ef73e918114383e9479af86a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000792977.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))